Best deals to access real time data! |
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 62.85 ▲ 0.22 (0.35%) | |
| Company Name | Stock Ticker Symbol | Market | Type | ISIN |
|---|---|---|---|---|
| Merck & Company (New) | MRK | NYSE | Ordinary Share | US58933Y1055 |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.31 | -0.49% | 62.63 | 63 | 62.58 | 62.79 | 62.94 | 16:42:40 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 37,191 | 6,906,447 | $ 62.7147 | $ 433.14M | 7.27M | 57.18 - 66.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:38:27 | formt | 50 | $62.85 | USD |
| Industry Sector |
|---|
| Drug Manufacturers - Major |
Merck & Company (New) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 171.3B | 2.74B | $ 3.92B | 1.42 | 44.30 | 2.74B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 16.84M | $ 1.88 | 3.00% | 06/13/2017 | -5.14k | 71.60% |
Merck & Company (New) News
European Medicines Agency’s CHMP Recommends Approval for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain ... Business Wire • Fri Jul 21, 2017 7:31 AM (2 days ago)
Merck Announces U.S. FDA Grants Tentative Approval for LUSDUNA™ Nexvue™ (insulin glargine injection), a Follow-On Biologi... Business Wire • Thu Jul 20, 2017 7:30 AM (3 days ago)
Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer’s Association International Conference® Business Wire • Mon Jul 17, 2017 7:00 AM (6 days ago)
ALK - Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children PR Newswire (US) • Fri Jul 07, 2017 5:00 AM (2 weeks ago)
Merck to Hold Second-Quarter 2017 Sales and Earnings Conference Call on July 28 Business Wire • Thu Jul 06, 2017 5:45 PM (2 weeks ago)
Merck to Present New Data from Clinical Trials Evaluating ISENTRESS® HD (raltegravir) & Investigational HIV Therapies Doravi... Business Wire • Thu Jul 06, 2017 7:00 AM (2 weeks ago)
FDA Suspends Certain Clinical Trials of Merck's Keytruda Dow Jones News • Wed Jul 05, 2017 6:55 PM (2 weeks ago)
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRK Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 62.93 | 63.395 | 62.27 | 0.0000 | 5M | 7M | 6M | -0.3 | -0.48% |
| 1 Month | 66.04 | 66.4 | 62.24 | 0.0000 | 5M | 11M | 7M | -3.41 | -5.16% |
| 3 Months | 62.58 | 66.4 | 62.1 | 0.0000 | 3M | 18M | 8M | 0.05 | 0.08% |
| 6 Months | 62.4 | 66.8 | 60.54 | 0.0000 | 3M | 22M | 8M | 0.23 | 0.37% |
| 1 Year | 58.99 | 66.8 | 57.18 | 0.0000 | 3M | 69M | 9M | 3.64 | 6.17% |
| 3 Years | 58.13 | 66.8 | 45.69 | 0.0000 | 0 | 69M | 9M | 4.5 | 7.74% |
| 5 Years | 43.75 | 66.8 | 40.02 | 0.0000 | 0 | 69M | 11M | 18.88 | 43.15% |
Merck & Company (New) Description
| Merck & Co Inc is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. |
